指南与共识儿科与产科急症重症综合管理与镇静镇痛

孕产妇与新生儿健康研究和监测新发及持续流行威胁的核心结局集(MNH-EPI-COS):基于改良德尔菲法的国际共识

A core outcome set for maternal and neonatal health research and surveillance of emerging and ongoing epidemic threats (MNH-EPI-COS): a modified Delphi-based international consensus.
指南 / 共识 · EClinicalMedicine · 2025-01-15
一句话结论MNH-EPI-COS国际共识确立7项孕产妇主结局、7项补充结局及11项新生儿主结局、4项补充结局,用于疫情期母婴健康研究与监测的标准化报告。

该研究通过系统综述和四阶段改良德尔菲共识,制定孕产妇与新生儿健康在疫情威胁下研究与监测的核心结局集(COS)。150名国际利益相关者参与在线调查,24名代表参与共识会议;结局纳入标准为≥80%参与者评为至关重要且≤10%评为不重要。最终COS包含7项孕产妇主结局、7项孕产妇补充结局、11项新生儿主结局及4项新生儿补充结局。该COS有望标准化母婴结局的选择与报告,促进数据比较和及时循证决策。

要点

  • 最终COS纳入7项孕产妇主结局:妊娠结局、孕产妇死亡、疑似症状性感染、确诊感染、重症、早产、分娩方式。
  • 孕产妇补充结局7项:产前出血、产后出血、妊娠期高血压疾病、孕产妇脓毒症、ICU/特殊病房入住、呼吸支持、抑郁和焦虑。
  • 新生儿主结局11项:新生儿死亡、疑似症状性感染、确诊感染、重症、垂直传播、低出生体重、早产、先天性疾病、呼吸支持、皮肤接触、母乳喂养。
  • 新生儿补充结局4项:新生儿ICU/特殊病房入住、呼吸衰竭、出生窒息、脓毒症。
  • 结局纳入共识阈值:≥80%参与者评为至关重要且≤10%评为不重要。

适用人群与场景

  • 孕产妇与新生儿健康研究及监测中,面临新发和持续流行威胁的人群。

诊断标准与关键阈值

  • 结局纳入标准:≥80%的参与者评分为至关重要,且≤10%的参与者评为不重要。

研究设计与关键结果

  • 系统综述观察性和实验性流行病相关研究以识别结局,并进行四阶段改良德尔菲共识。
  • 150名国际利益相关者参与在线调查,24名代表参与共识会议;专家组成员背景多样,专业背景、性别和地域代表性均衡,包括民间社会代表。
  • 最终COS包括7项孕产妇主结局、7项孕产妇补充结局、11项新生儿主结局和4项新生儿补充结局。

证据类型、等级与局限

  • 证据类型:基于系统综述和改良德尔菲共识的国际共识(指南类)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该COS可能有助于标准化观察性和实验性研究中孕产妇和新生儿结局的选择与报告,促进在持续和新发流行病威胁背景下高效的数据比较和及时的循证决策。

指南或共识出处

  • MNH-EPI-COS国际共识(EClinicalMedicine发布)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Disease outbreaks significantly affect maternal and neonatal health. Variability in reporting health outcomes hinder evidence generation. We aimed to develop a core outcome set (COS) for maternal and neonatal health research and surveillance during emerging and ongoing epidemic threats and to agree on outcomes' definitions.

METHODS: We conducted a systematic review of observational and experimental studies related to epidemics to identify outcomes, and a four-stage modified-Delphi consensus. 150 international stakeholders participated in online surveys, and 24 representatives in consensus meetings. The panels were diverse, with balanced representation of professional background, gender, and geography, including civil society representatives. Outcome were included if ≥ 80% of participants scored them as critically important and ≤10% rated them as not important.

FINDINGS: The final COS includes seven main maternal outcomes-pregnancy outcome, maternal death, suspected symptomatic infection, confirmed infection, severe disease, preterm delivery, mode of birth; seven complementary maternal outcomes-antepartum haemorrhage, postpartum haemorrhage, hypertensive disorders of pregnancy, maternal sepsis, admission to intensive care unit/special units, respiratory support, depression and anxiety; 11 main neonatal outcomes-neonatal death, neonatal suspected symptomatic infection, confirmed infection, severe disease, vertical transmission, low birth weight, prematurity, congenital disorder, respiratory support, skin-to-skin contact, breastfeeding; and, four complementary neonatal outcomes-admission to neonatal intensive care unit/special units, respiratory failure, birth asphyxia, sepsis.

INTERPRETATION: This COS could contribute to standardize maternal and neonatal outcomes selection and reporting in observational and experimental studies, facilitating efficient data comparison and timely evidence-based decision-making in the context of ongoing and emerging epidemic threats.

FUNDING: Bill & Melinda Gates Foundation (grant INV-041181) and the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), a cosponsored programme executed by the World Health Organization (HQHRP2422779).

来源:EClinicalMedicine,查看原文。版权归原作者所有。

参考来源

  1. Pingray V, Klein K, Alonso JP, et al. A core outcome set for maternal and neonatal health research and surveillance of emerging and ongoing epidemic threats (MNH-EPI-COS): a modified Delphi-based international consensus. EClinicalMedicine. 2025. PMID: 39896875. doi:10.1016/j.eclinm.2024.103025

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。